■ TearClear’s latanoprost ophthalmic solution 0.005% met the primary and all secondary endpoints in the CLEAR phase 3 trial, and the company plans to file an NDA this year. The product “will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multidose bottles,” according to the company. The product contains the preservative BAK while in the bottle, but the drops are delivered without the preservative.

Glaucoma is treated in many cases, with multiple eye drops, said Thomas Samuelson, MD, a founding partner of Minnesota Eye Consultants. “The BAK-containing formulas are many times delivering a high dose of the preservative. If we can keep the BAK in the bottle, but once the eyedrop hits the surface of the eye, it’s BAK-free, that’s really the best of both worlds,” he said in a company news release.